DB05438ExperimentalProtein Based Therapies
IDM-4 is an immuno-designed molecule that completed phase I/II of investigation for the treatment of Leukemia. It is a monoclonal antibody-specific antigen that can selectively target cancer-affected cells by coupling... Trials of this drug have most likely been discontinued by the manufacturer.
- Mechanism
- Curator reviewed
The lipid promotes fusion of liposomes to cells. Specifically, IDM-4 targets tumor cells by coupling MAK cells with tumor antigens obtained from the patient.
- Primary indication
- Investigated for use/treatment in leukemia (lymphoid).Curator reviewed
Which companies are running trials of IDM-4, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account